Probi AB (publ) appoints new CFO
Probi AB (publ), a leading provider of probiotic solutions, is pleased to announce the appointment of Per Lindblad as the company's new CFO. Per will start his assignment by the 1st of November, 2023.
"We are delighted to welcome Per to the Probi team," said Anita Johansen, CEO of Probi. "With his extensive experience from specialty ingredients industries, including probiotics, and his solid expertise as a finance business partner, we are confident that he will help us achieve our strategic objectives."
Per joins Probi from ABF Ingredients where he served as CFO. Previous to ABF Ingredients, Per had senior leadership roles in finance in Chr. Hansen and CP Kelco.Throughout his career, he has demonstrated exceptional leadership skills and a deep understanding of financial management and business development.
"I am excited to be joining Probi at such an exciting time in the company's journey," said Per Lindblad. "I look forward to working closely with the leadership team to provide value to our shareholders by supporting Probi's mission of providing probiotics for healthier lives and a healther planet."
This information is information that Probi AB is obliged to make public according to the EU's Market Abuse Regulation. The information was submitted, through the care of the contact persons below, for publication on 20 October 2023 at 11.00 CET. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
For further information, please contact:
Anita Johansen, CEO, Probi, Phone: +46 46 286 89 48, E-mail: [email protected]
ABOUT PROBI AB (publ)
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.
